Zacharski L R, Memoli V A, Rousseau S M
Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire.
Cancer. 1988 Jul 15;62(2):299-302. doi: 10.1002/1097-0142(19880715)62:2<299::aid-cncr2820620212>3.0.co;2-#.
Thrombin-generated cleavage sites of human fibrinogen have been identified adjacent to viable tumor cells in fresh frozen sections of small cell carcinoma of the lung (SCCL) by means of immunohistochemical techniques using mouse monoclonal antibodies to the N-terminal peptides of the fibrinogen alpha and beta chains. These results indicate that thrombin is generated in situ in this tumor type. Based on previous evidence for the existence of an initiator of coagulation together with coagulation factor intermediates associated with viable SCCL tumor cells in situ, and also for the favorable effects of anticoagulant therapy with warfarin in SCCL, we postulate that local tumor cell-induced thrombin formation may contribute to self-regulated progression of SCCL through deposition of fibrin and stimulation of cell proliferation. These results suggest novel treatment strategies for this particular tumor type and justify efforts to identify other tumor types in which similar mechanisms exist.
通过使用针对纤维蛋白原α链和β链N端肽的小鼠单克隆抗体的免疫组织化学技术,已在肺小细胞癌(SCCL)新鲜冰冻切片中,在存活肿瘤细胞附近鉴定出人类纤维蛋白原的凝血酶生成切割位点。这些结果表明,在这种肿瘤类型中凝血酶是原位生成的。基于先前存在凝血启动因子以及与存活的SCCL肿瘤细胞原位相关的凝血因子中间体的证据,以及华法林抗凝治疗对SCCL的有利影响,我们推测局部肿瘤细胞诱导的凝血酶形成可能通过纤维蛋白沉积和细胞增殖刺激促进SCCL的自我调节进展。这些结果为这种特殊肿瘤类型提出了新的治疗策略,并证明有必要努力识别存在类似机制的其他肿瘤类型。